Skip to content
The Policy VaultThe Policy Vault

Imbruvica (ibrutinib) — Medica

B-Cell Lymphoma (including diffuse large B-cell lymphoma, HIV-related B-cell lymphoma, post-transplant lymphoproliferative disorder, high-grade B-cell lymphoma)

Initial criteria

  • Patient is age ≥ 18 years
  • Patient has tried at least one systemic regimen (e.g., cisplatin, cytarabine, rituximab, oxaliplatin, gemcitabine, ifosfamide, carboplatin, etoposide)

Reauthorization criteria

  • Patient continues to meet initial criteria

Approval duration

1 year